J. Scott Applewhite / AP

It's about stocks, again. CNN notices the Georgia Republican, who is Trump's nominee to lead HHS, introduced legislation delaying regulation on a company in which he'd recently purchased stock. The transition team says there's no scandal — the purchase was made by a broker and Price didn't know about it until after the bill was introduced.

What happened:

  • The Centers for Medicare and Medicaid Services proposed a new way to pay for drugs under Medicare Part B last year. It was ultimately withdrawn by the administration after the election, but drew vehement industry and congressional criticism.
  • Price, then chair of the House Budget Committee, bought stock in Zimmer Biomet shortly before introducing the delay bill. Analysts had said the Zimmer Biomet, a medical device manufacturer, would be significantly hurt by the regulation.
  • Zimmer Biomet's political action committee then contributed to Price's re-election campaign.
  • In a statement Monday night, the transition team said the purchase happened because Price's broker was doing a larger rebalancing of his portfolio and he didn't know about it until later.

What's next: If this sounds familiar, it's because Price's stock purchases have come up repeatedly in the past couple weeks, raising ethical questions. But the real question is whether it's a big enough deal to sink his nomination.

So far, the answer seems to be probably not. "It's hardly surprising he introduced a bill to overturn a badly written reg," said one Senate GOP aide. The aide also pointed out the bill had likely been drafted for awhile before it was introduced, which is standard law-writing process.

Go deeper

Updated 19 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 11:30 p.m. ET: 31,478,387 — Total deaths: 968,726 Total recoveries: 21,622,862Map.
  2. U.S.: Total confirmed cases as of 11:30 p.m. ET: 6,895,685 — Total deaths: 200,768 — Total recoveries: 2,646,959 — Total tests: 96,612,436Map.
  3. Health: The U.S. reaches 200,000 coronavirus deaths — The CDC's crumbling reputation — America turns against coronavirus vaccine.
  4. Politics: Elected officials are failing us on much-needed stimulus.
  5. Business: Two-thirds of business leaders think pandemic will lead to permanent changes — Fed chair warns economy will feel the weight of expired stimulus.
  6. Sports: NFL fines maskless coaches.

Trump pushes to expand ban against anti-racism training to federal contractors

Trump speaking at Moon Township, Penns., on Sept. 22. Photo: Mandel Ngan/AFP via Getty Images

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Dan Primack, author of Pro Rata
4 hours ago - Economy & Business

GoodRx prices IPO at $33 per share, valued at $12.7 billion

Illustration: Sarah Grillo/Axios

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday night raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!